Loading...

BICO Group AB (publ)

BCCOYPNK
Healthcare
Medical - Devices
$0.80
$0.00(0.00%)

BICO Group AB (publ) (BCCOY) Financial Performance & Income Statement Overview

Explore the financials of BICO Group AB (publ) (BCCOY), including yearly and quarterly data on income, cash flow, and balance sheets.

Revenue Growth
-3.19%
3.19%
Operating Income Growth
48.99%
48.99%
Net Income Growth
99.53%
99.53%
Operating Cash Flow Growth
-11.21%
11.21%
Operating Margin
-27.61%
27.61%
Gross Margin
81.74%
81.74%
Net Profit Margin
-37.32%
37.32%
ROE
-12.22%
12.22%
ROIC
-6.68%
6.68%

BICO Group AB (publ) (BCCOY) Income Statement & Financial Overview

View the income breakdown for BICO Group AB (publ) BCCOY across both annual and quarterly reports.

MetricQ1 2025Q4 2024Q3 2024Q2 2024
Revenue$388.60M$570.80M$495.50M$534.00M
Cost of Revenue$178.70M$242.70M$232.30M$259.00M
Gross Profit$209.90M$328.10M$263.20M$275.00M
Gross Profit Ratio$0.54$0.57$0.53$0.51
R&D Expenses$56.80M$70.40M$68.50M$91.10M
SG&A Expenses$80.60M$274.00M$251.60M$247.20M
Operating Expenses$288.90M$331.20M$312.70M$325.00M
Total Costs & Expenses$467.70M$573.90M$545.00M$584.00M
Interest Income$21.50M$285.60M$3.60M$7.80M
Interest Expense$174.20M$27.20M$188.10M$43.80M
Depreciation & Amortization$34.00M$0.00$0.00$0.00
EBITDA-$23.60M$407.70M-$45.90M-$42.10M
EBITDA Ratio-$0.06$0.71-$0.09-$0.08
Operating Income-$79.10M-$3.10M-$49.50M-$50.00M
Operating Income Ratio-$0.20-$0.005-$0.10-$0.09
Other Income/Expenses (Net)-$152.70M$258.50M-$184.50M-$35.90M
Income Before Tax-$231.80M$255.30M-$234.00M-$85.90M
Income Before Tax Ratio-$0.60$0.45-$0.47-$0.16
Income Tax Expense$3.30M-$2.60M$13.50M-$7.30M
Net Income-$234.00M$346.80M-$246.20M-$77.90M
Net Income Ratio-$0.60$0.61-$0.50-$0.15
EPS-$3.32$4.91-$3.49-$1.10
Diluted EPS-$3.32$4.75-$3.49-$1.10
Weighted Avg Shares Outstanding$70.57M$70.57M$70.57M$70.57M
Weighted Avg Shares Outstanding (Diluted)$72.71M$73.00M$70.57M$70.57M

The company's financials show resilient growth, with revenue advancing from $534.00M in Q2 2024 to $388.60M in Q1 2025. Gross profit remained healthy with margins at 54% in Q1 2025 compared to 51% in Q2 2024. Operating income hit -$79.10M last quarter, sustaining a consistent -20% margin. Changes in R&D and SG&A spending did not hinder EBITDA, which stood at -$23.60M. Net income dropped to -$234.00M, while earnings per share reached -$3.32. Strong cost management and operational efficiency kept profitability intact, underlining the company's stable and competitive market performance.

Unlock 25+ Years of Financial Data

Get access to extended historical data, advanced metrics, and more with our premium plan

Frequently Asked Questions

;